Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2fludarabine phosphate 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Cyclosporine 2Caspofungin 2Carboplatin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ibrutinib 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Whole-Body Irradiation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Monoclonal Gammopathy of Undetermined Significance × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡